AIRS Stock — Airsculpt Technologies, Inc.

Up next

Next earnings call

Nov 14, 2026 Est · unconfirmed · in 6 wks

Latest filing: 10-Q

filed Aug 10, 2026

Q1 2026 earnings call transcript

call held May 8, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

-79.1%

Trailing year

Short interest

4.3%

Latest settlement · 3.2 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 10, 2026

Q2 FY26

TL;DR. AirSculpt reported Q2 revenue down 3% to $42.9M with adjusted EBITDA of $4.9M (vs. $5.8M), cut its full-year adjusted EBITDA outlook to $12–$14M, and reaffirmed revenue at the low end of $151–$157M; same-center cases grew 1% and the company expanded its AlloClae partnership and new procedures, while customer acquisition cost rose to ~$3,500 from $2,900.

Bullish

+ Same-center case volume grew 1.0% in Q2 and 1.1% YTD versus prior year.
+ Entered an exclusive AlloClae partnership and is piloting the new procedure later this quarter.
+ Skin tightening and skin removal procedures carry similar ~60% gross margin profile to core fat removal business and lift average ticket.

Bearish

− Q2 revenue declined 3% to $42.9M and YTD revenue fell 1.3% to $82.3M.
− Adjusted EBITDA fell to $4.9M in Q2 from $5.8M and YTD to $8.2M from $9.6M, with margins compressing to 11.5%/10.0% from 13.3%/11.5%.
− Full-year 2026 adjusted EBITDA outlook reduced to approximately $12–$14M.
− Full-year 2026 revenue reaffirmed only at the lower end of the $151–$157M guidance range.
− Q2 customer acquisition cost rose to ~$3,500 from ~$2,900 a year ago, lifting marketing to ~20% of revenue from ~18%.
− Q2 net loss widened to $1.1M from $0.6M and YTD net loss to $3.5M from $3.4M.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 16.4 · calm Equity put/call 0.57

Technical

price trend

Strong Sell

50 / 200-day cross Death cross

Price vs 200-day avg −47%

below

Price vs 50-day avg −44%

below

RSI (14) 28

oversold

MACD trend Negative

52-week position 1%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −31%

trailing

6-month return −36%

trailing

YTD return −14%

this year

Relative strength −48%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) Death cross

50d $3 › 200d $3 — 200d above 50d

Institutional flow Accumulating

+14% holders QoQ · +25 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

4.26% of float · ▲ +2.1% MoM · 3.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

103 holders — near 3-yr high, broad support

Squeeze score 46

elevated · 0–100

Fundamentals

Weak

Revenue growth −16%

Y/Y

EPS growth −36%

Y/Y

Free cash flow $692.0K

Balance sheet $47.6M

net debt

Quant / Vol

risk profile

Very High

Volatility 129%

annualized · 1-yr

Max drawdown −86%

past year

ATR 12.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 1 of last 2

Latest guidance · from the 8-K filed Aug 10, 2026

Revenue · full year 2026 Initiated $151M – $157M

prior FY $151.82M midpoint +1.4% Y/Y

Adjusted EBITDA · full year 2026 Non-GAAP Initiated $12M – $14M

Guided vs delivered · last 2 settled

Revenues full year 2024

guided $180M – $190M

guided $180M – $190M $180.35M In line

2023 revenue full year 2023

guided $196M

guided $196M $195.92M Miss −0.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell

5 · 2 · 0

50 / 200-day cross

Death cross Bearish

Price vs 200-day avg

−47% Bearish

Price vs 50-day avg

−44% Bearish

RSI (14)

28 Neutral

MACD trend

Negative Bearish

52-week position

1% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) Death cross

50d $3 › 200d $3 — 200d above 50d

Institutional flow Accumulating

+14% holders QoQ · +25 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

4.26% of float · ▲ +2.1% MoM · 3.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

103 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $2 · 1% Range high $12

vs 200-day avg -47% vs 50-day avg -44% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	$8.25M	Six Months Ended June 30, 2026	—
Adjusted EBITDA margin non-GAAP	10%	Six Months Ended June 30, 2026	—
Adjusted net (loss)/income non-GAAP	-$211K	Six Months Ended June 30, 2026	—
Adjusted Net Income per share - Basic non-GAAP	$0.01	Three Months Ended June 30, 2026 filing	—
Adjusted Net Income per share - Diluted non-GAAP	$0.01	Three Months Ended June 30, 2026 filing	—
Adjusted net loss per share of common stock - Basic non-GAAP	$0	Six Months Ended June 30, 2026	—
Adjusted net loss per share of common stock - Diluted non-GAAP	$0	Six Months Ended June 30, 2026	—
Case growth	-0.5%	Three Months Ended June 30, 2026 filing	—
Cases	6,458	Six Months Ended June 30, 2026	—
Customer acquisition costs	$3,467	the three months ended June 30, 2026 filing	—
Number of facilities	31	Q2 2026	—
Number of total procedure rooms	65	Q2 2026	—
Revenue per case	$12,742	Six Months Ended June 30, 2026	—
Revenue per case growth	-2.1%	Three Months Ended June 30, 2026 filing	—
Same center case volume growth	1%	Q2 2026	—
Same-center Cases	6,458	Six Months Ended June 30, 2026	—
Same-center Number of facilities	31	Six Months Ended June 30, 2026	—
Same-center Number of total procedure rooms	65	Six Months Ended June 30, 2026	—
Same-center Revenue per case	$12,742	Six Months Ended June 30, 2026	—
Same-center Revenue per case growth	-2%	Three Months Ended June 30, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AIRS Airsculpt Technologies, Inc. this stock	$139.14M	-14.1%	-15.8%	—	4.3%
HCA HCA Healthcare, Inc.	$96.64B	-9.3%	+7.1%	15.0	2.9%
FSNUY Fresenius SE & Co. KGaA	$29.92B	-13.1%	—	—	0.0%
THC Tenet Healthcare Corp	$20.91B	+27.8%	+0.9%	10.0	2.5%
EHC Encompass Health Corp	$12.18B	+12.2%	+10.5%	20.1	3.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

103

% held: 64.0%
Net QoQ: +3.9M sh
Top holder: Vesey Street Capital Part…

Held Float

View

Held by Funds

Fund positions

82

View

Short & Settlement

Short Interest Rising

Shares short

3.1M

Days to cover: 3.2d
Change: +63.7K sh

View

Short Volume

Short vol %

38%

As of: Oct 1, 2026

Short Total

View

Fails to Deliver

FTD shares

30.0K

Value: $81.3K
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

49.1%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$151.8M

Net income (FY): $-11.7M
EPS diluted: $-0.19

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 12, 2026
This year: 15

View

Proposed Sales

Value

$16.7K

Shares: 2.6K
Filed: Nov 15, 2024

View

Earnings & Events

Webcasts

Last webcast

Aug 11, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
AIRS	-16.3%	-30.9%	-35.6%	-3.4%	-14.1%
SPY	-0.4%	-0.2%	+12.4%	+0.2%	+12.0%
vs SPY	-15.8%	-30.7%	-48.1%	-3.6%	-26.2%

AIRS · Airsculpt Technologies, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance